Category: Latest News
-
Dow Jones, S&P, Nasdaq, Wall Street Futures Edge Up Ahead of Inflation Reports
U.S. stock futures indicate a modestly higher open on Monday as investors weigh last week’s mixed market performance and weaker-than-expected payroll figures. Despite pulling back from intraday lows on Friday, the major indexes still closed slightly lower. Friday’s Labor Department report showed U.S. nonfarm payrolls rose just 22,000 in August, well below economists’ forecast of…
-
Regeneron Reports Positive Phase 3 Results, Boosting Allergy Treatment Pipeline
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced that its first-in-class antibody-blocker therapies for cat and birch allergies have achieved positive outcomes in two Phase 3 clinical trials. The company confirmed that both trials met their primary and secondary endpoints, demonstrating strong efficacy in reducing allergic responses. The combination therapy was well-tolerated, with no serious adverse events reported…
-
Dianthus Therapeutics Shares Jump After Promising Phase 2 gMG Trial Results
Shares of Dianthus Therapeutics (NASDAQ:DNTH) soared 65% following the release of positive results from its Phase 2 trial of claseprubart, an experimental therapy for generalized Myasthenia Gravis (gMG). The company reported that both 300mg and 600mg doses of claseprubart, administered every two weeks, achieved statistically significant and clinically meaningful improvements in key efficacy measures. Patients…
-
Ideaya Biosciences Shares Climb Following Strong Early Lung Cancer Trial Data
Shares of Ideaya Biosciences (NASDAQ:IDYA) surged 10% in premarket trading Monday after the company reported promising preliminary results from an early-stage study of its lung cancer treatment. The Phase 1 trial assessed IDE849 (SHR-4849), developed in collaboration with Hengrui Pharma, for patients with small cell lung cancer. Initial findings indicated an overall response rate of…
-
Summit Therapeutics Shares Plunge After Lung Cancer Drug Data Disappoints
Summit Therapeutics (NASDAQ:SMMT) saw its stock drop 23% in premarket trading after the company released updated longer-term follow-up data from its global trial of the investigational lung cancer therapy, ivonescimab. The new data failed to replicate the promising results previously observed in Chinese studies, raising concerns among investors and analysts. Findings indicated potential overall survival…
-
Premier Shares Jump Amid Rumors of Patient Square Capital Acquisition Talks
Shares of Premier Inc (NASDAQ:PINC) climbed more than 8% in premarket trading on Monday after a Bloomberg News report suggested that Patient Square Capital is exploring a potential acquisition of the healthcare services company. The report, released Friday, cited sources familiar with the discussions, noting that negotiations are still in the early stages. There is…
-
Rapport Therapeutics Surges After Promising Mid-Stage Seizure Drug Trial
Shares of Rapport Therapeutics (NASDAQ:RAPP) skyrocketed 160% after the biotech firm released encouraging topline data from a Phase 2a study of its experimental therapy RAP-219 in patients with focal onset seizures. The trial achieved its primary endpoint with strong statistical significance, showing a 71% median reduction in long seizure episodes, a recognized electrographic marker of…
-
Planet Labs Jumps After Delivering Record Revenue and Upbeat Outlook
Planet Labs PBC (NYSE:PL) saw its shares climb more than 9% in pre-market trading on Monday after unveiling second-quarter results that beat Wall Street forecasts and came with a brighter outlook for the year. For the quarter ending July 31, 2025, the Earth imaging company generated $73.4 million in revenue, up 20% from the same…
-
Eli Lilly’s Jaypirca hits key milestone in leukemia study
Eli Lilly (NYSE:LLY) reported that its phase 3 study of Jaypirca achieved the main goal in treating patients with chronic lymphocytic leukemia (CLL). According to the company, results from the BRUIN CLL-313 and BRUIN CLL-314 trials will serve as the foundation for applications to expand the drug’s approved use into earlier stages of treatment. The…
-
Tesla’s U.S. EV Market Share Slips to Lowest Level Since 2017
Tesla’s (NASDAQ:TSLA) dominance in the American electric vehicle market continued to weaken in August, with its share dropping to levels not seen in nearly eight years, according to a Reuters report citing Cox Automotive data. Figures showed that Tesla represented just 38% of U.S. EV sales last month, falling under the 40% mark for the…